Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show bene...

Full description

Bibliographic Details
Main Authors:	Schilling, WHK, Mukaka, M, Callery, JJ, Llewelyn, MJ, Cruz, CV, Dhorda, M, Ngernseng, T, Waithira, N, Ekkapongpisit, M, Watson, JA, Chandna, A, Nelwan, EJ, Hamers, RL, Etyang, A, Beg, MA, Sow, S, Yavo, W, Allabi, AC, Basnyat, B, Sharma, SK, Amofa-Sekyi, M, Yonga, P, Adler, A, Yuentrakul, P, Abdad, MY, Blacksell, SD, Tarning, J, Rahardjani, M, Rimainar, A, Akech, S, Hamaluba, M, Shrestha, S, Rijal, S, Woodrow, CJ, Cheah, PY, Taylor, WRJ, Batty, EM, von Seidlein, L, Dondorp, A, Day, NPJ, White, NJ
Format:	Journal article
Language:	English
Published:	Public Library of Science 2024

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Similar Items